|
|
News Breaks
|
October 27, 2009
|
| 08:31 EDT |  | POZN |
| theflyonthewall.com: | Phase i study shows POZEN's PA65020 effective | | POZEN Inc. announced the results of a Phase I study that showed a novel, investigational combination of enteric-coated aspirin and immediate-release omeprazole known as PA65020, is associated with a significantly decreased risk of GI mucosal damage compared to analgesic doses of over-the-counter enteric-coated aspirin in healthy adults treated for one month. The randomized, double-blind study highlighted that the majority of patients taking over-the-counter EC-ASA experienced significant gastroduodenal damage. The data were presented at the American College of Gastroenterology 2009 Annual Scientific Meeting today in San Diego, CA. ACG presented the study with a Presidential Award for winning science. :theflyonthewall.com |
|
|
News For POZN From The Last 14 Days Check below for free stories on POZN the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
